This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 Jul;78(4):331-4.

doi: 10.1016/j.jbspin.2011.01.005. Epub 2011 Feb 25.

"Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?"

Ugo Fiocco, Leonardo Punzi

PMID: 21353617
DOI: 10.1016/j.jbspin.2011.01.005

Editorial

"Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?"

Ugo Fiocco et al. Joint Bone Spine. 2011 Jul.

. 2011 Jul;78(4):331-4.

doi: 10.1016/j.jbspin.2011.01.005. Epub 2011 Feb 25.

Authors

Ugo Fiocco, Leonardo Punzi

PMID: 21353617
DOI: 10.1016/j.jbspin.2011.01.005

No abstract available

PubMed Disclaimer

Similar articles

Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV. Voulgari PV. Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49. Expert Rev Clin Immunol. 2010. PMID: 20828280 Review.
Golimumab - a new tool in the armoury against inflammatory arthritis.
Ash Z, Emery P. Ash Z, et al. Ann Med. 2011 Mar;43(2):133-41. doi: 10.3109/07853890.2010.549148. Epub 2011 Jan 18. Ann Med. 2011. PMID: 21244218 Review.
Golimumab (simponi) for inflammatory arthritis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Jul 13;51(1316):55-6. Med Lett Drugs Ther. 2009. PMID: 19590489 No abstract available.
Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C. Campas-Moya C. Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434. Drugs Today (Barc). 2010. PMID: 20200692 Review.
[RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Anić B, Babić-Naglić Ð, Grazio S, Kehler T, Kaliterna DM, Radoncić KM, Morović-Vergles J, Novak S, Prus V, Vlak T, Baresić M. Anić B, et al. Reumatizam. 2015;62(1):12-9. Reumatizam. 2015. PMID: 27024887 Croatian.

See all similar articles

Cited by

Exploration of comorbidity mechanisms and potential therapeutic targets of rheumatoid arthritis and pigmented villonodular synovitis using machine learning and bioinformatics analysis.
Heng H, Li D, Su W, Liu X, Yu D, Bian Z, Li J. Heng H, et al. Front Genet. 2023 Jan 6;13:1095058. doi: 10.3389/fgene.2022.1095058. eCollection 2022. Front Genet. 2023. PMID: 36685864 Free PMC article.
Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors.
Koarada S, Tsuboi M, Komine M, Nakao Y, Tokuda Y, Ono Y, Tashiro S, Maruyama A, Ono N, Ohta A, Tada Y. Koarada S, et al. Case Rep Rheumatol. 2015;2015:348614. doi: 10.1155/2015/348614. Epub 2015 Sep 14. Case Rep Rheumatol. 2015. PMID: 26451269 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information